Variability (MR vs. IR) [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2013-09-12 17:23 (3662 d 09:00 ago) – Posting: # 11485
Views: 12,102

Dear all,

one goody slipped trough my attention, namely lines 340–344:

The inter-individual variability of the pharmacokinetic parameters of interest should be deter­mined in the single dose or multiple dose studies […] and should be compared between the modified and immediate release formulation. The variability of the modified release formulation should preferably not exceed that of the immediate release formulation.

OK, but how to do that? I guess one-sided (non-superiority) of inter-subject variance is meant. But the inter-subject variance is only accessible in a crossover or a paired design: If we have a SD and a MD study we can only assess the total (pooled) variance.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,759 posts in 4,775 threads, 1,627 registered users;
16 visitors (0 registered, 16 guests [including 11 identified bots]).
Forum time: 02:23 CEST (Europe/Vienna)

A refund for defective software might be nice,
except it would bankrupt the entire software industry
in the first year.    Andrew S. Tanenbaum

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5